Delayed
Hong Kong S.E.
23:08:00 2024-04-29 EDT
|
5-day change
|
1st Jan Change
|
10.26
HKD
|
-2.10%
|
|
+1.58%
|
-17.52%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
6,907
|
3,769
|
3,174
|
3,174
|
-
|
Enterprise Value (EV)
1 |
3,987
|
2,578
|
3,704
|
2,180
|
2,164
|
P/E ratio
|
-
|
-33.4
x
|
-47.1
x
|
44.1
x
|
19.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
38.8
x
|
11.3
x
|
7.02
x
|
4.16
x
|
2.92
x
|
EV / Revenue
|
22.4
x
|
7.72
x
|
7.02
x
|
2.86
x
|
1.99
x
|
EV / EBITDA
|
-19.4
x
|
-13
x
|
-44.9
x
|
28.7
x
|
13.8
x
|
EV / FCF
|
-
|
-11.4
x
|
-8.25
x
|
-14.9
x
|
-33.8
x
|
FCF Yield
|
-
|
-8.77%
|
-12.1%
|
-6.7%
|
-2.96%
|
Price to Book
|
1.95
x
|
1.21
x
|
1.04
x
|
1.04
x
|
0.98
x
|
Nbr of stocks (in thousands)
|
332,401
|
332,401
|
327,458
|
327,458
|
-
|
Reference price
2 |
20.78
|
11.34
|
9.694
|
9.694
|
9.694
|
Announcement Date
|
22-03-15
|
23-03-29
|
24-03-21
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
27.63
|
177.9
|
334.1
|
527.8
|
763.6
|
1,087
|
EBITDA
1 |
-
|
-205.9
|
-198
|
-47.4
|
76
|
157.2
|
EBIT
1 |
-
|
-212.5
|
-208.4
|
-156.5
|
51
|
160.5
|
Operating Margin
|
-
|
-119.43%
|
-62.38%
|
-29.66%
|
6.68%
|
14.76%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-113.6
|
-78.73
|
76.33
|
171.3
|
Net income
1 |
-
|
-
|
-113.6
|
-78.73
|
72
|
161.3
|
Net margin
|
-
|
-
|
-33.99%
|
-14.92%
|
9.43%
|
14.84%
|
EPS
2 |
-0.5200
|
-
|
-0.3400
|
-0.2400
|
0.2200
|
0.4867
|
Free Cash Flow
1 |
-
|
-
|
-226.1
|
-258
|
-146
|
-64
|
FCF margin
|
-
|
-
|
-67.66%
|
-51.16%
|
-19.12%
|
-5.89%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-06-22
|
22-03-15
|
23-03-29
|
24-03-21
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
2,919
|
1,191
|
1,046
|
994
|
1,011
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-226
|
-258
|
-146
|
-64
|
ROE (net income / shareholders' equity)
|
-
|
-11.2%
|
-3.64%
|
0.09%
|
2.33%
|
4.72%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-3.49%
|
-0.57%
|
2.1%
|
4.37%
|
Assets
1 |
-
|
-
|
3,251
|
3,294
|
3,429
|
3,695
|
Book Value Per Share
2 |
-
|
10.70
|
9.370
|
9.320
|
9.340
|
9.870
|
Cash Flow per Share
2 |
-
|
-
|
-0.2800
|
0.0500
|
0.1200
|
0.3300
|
Capex
1 |
-
|
-
|
135
|
118
|
98.3
|
99.7
|
Capex / Sales
|
-
|
-
|
40.33%
|
23.33%
|
12.88%
|
9.17%
|
Announcement Date
|
21-06-22
|
22-03-15
|
23-03-29
|
24-03-21
|
-
|
-
|
Last Close Price
9.694
CNY Average target price
14.11
CNY Spread / Average Target +45.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.52% | 433M | | +13.16% | 128B | | -8.76% | 10.65B | | +3.60% | 8.82B | | +19.75% | 7.19B | | +22.28% | 4.99B | | +7.55% | 3.4B | | -0.21% | 3.03B | | -4.80% | 2.14B | | -4.72% | 2B |
Medical Devices & Implants
|